Indications
Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
Composition
- Active substance
- octreotide hydrochloride
- International name (INN)
- octreotide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Oczyesa
- Active substance
- octreotide hydrochloride
- ATC code
- H01CB02
- Therapeutic area
- Acromegaly
- Marketing authorisation holder
- Camurus AB
- Status
- Authorised